SCHEMBL18526660

SCHEMBL18526660

CC(C)(C)OC(=O)Nc1nc(Cc2ccccc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@H]2OC(C)(C)O[C@H]21

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PI4KA P42356 1/20 0.46
▸ PI4K2B Q8TCG2 1/20 0.46
▸ PI4K2A Q9BTU6 1/20 0.46
▸ PI4KB Q9UBF8 1/20 0.46
▸ NT5E P21589 4/20 0.44
▸ ADORA3 P0DMS8 5/20 0.41
▸ ADORA1 P30542 4/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ SLC29A1 Q99808 1/20 0.40
▸ PGK1 P00558 1/20 0.40
▸ PGK2 P07205 1/20 0.40
▸ P2RY12 Q9H244 1/20 0.39
▸ ADORA2A P29274 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18512583 0.94 NT5E (0.44) PI4KAPI4K2BPI4K2API4KBNT5E
SCHEMBL22001954 0.91 NT5E (0.45) PI4KAPI4K2BPI4K2API4KBNT5E
SCHEMBL17213465 0.86 NT5E (0.54) PI4KAPI4K2BPI4K2API4KBNT5E
SCHEMBL18493310 0.85 PI4KA (0.46) PI4KAPI4K2BPI4K2API4KBNT5E
SCHEMBL23566757 0.83 NT5E (0.43) PI4KAPI4K2BPI4K2API4KBNT5E
SCHEMBL20699834 0.82 PI4KA (0.62) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL18571809 0.82 PI4KA (0.62) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL12379237 0.82 PI4KA (0.62) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL18512573 0.79 PI4KA (0.38) PI4KAPI4K2BPI4K2API4KBNT5E
SCHEMBL24600772 0.78 NT5E (0.56) PI4KAPI4K2BPI4K2API4KBNT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170044203-A1 PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044203-A1 PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER ENTPD5, ENTPD1, NT5E PI4KA 1715/4885PI4K2B 2423/4885PI4K2A 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback